Descrizione del progetto
Adiuvanti sintetici per lo sviluppo di vaccini
La maggior parte dei vaccini contiene adiuvanti, ingredienti che aiutano a rafforzare le risposte immunitarie suscitate. Sono molti i composti impiegati come adiuvanti, che attivano le cellule che presentano l’antigene o preservano la conformazione degli antigeni che devono essere presentati. Il progetto ADJUVACCINE, finanziato dal CER, ha sviluppato una piattaforma per la sintesi di composti guida adiuvanti basati sulle saponine presenti in natura nelle piante. Le saponine hanno proprietà emulsionanti e schiumogene e recentemente sono state approvate come adiuvanti per i vaccini. La produzione sintetica di adiuvanti saponinici di ADJUVACCINE è scalabile, riduce i costi di produzione del vaccino e può essere integrata nella pipeline di produzione.
Obiettivo
ADJUVACCINE seeks to leverage a breakthrough made in the ERC-2016-STG-716878 project to validate a synthetic technological platform for the scalable production of identified optimised saponin adjuvants for improved cost-effective vaccines. We have developed in the laboratory potent, safe, stable, and streamlined adjuvant leads that surpass the QS-21 natural product adjuvant, leading to patent applications and the interest of Pharma. In this PoC project, we aim to exploit our synthetic saponin technology to produce adjuvant/vaccine candidates at scale that outperform existing products more cost-effectively, lowering the risk profile of the commercialisation potential, while also achieving valorisation outcomes for market entry. The goal is to demonstrate the scalability of our innovative adjuvant technology and select an optimal adjuvant candidate in advanced preclinical settings for entering the vaccine market via spin-off formation following proper IPR strategy implementation and attraction of key investors/partners.
The breakthrough innovation potential of ADJUVACCINE lies in the exploitation of this adjuvant platform for large-scale production and selection of the best candidate lead for application in vaccines against various diseases, improving the available vaccine solutions. The high purity and excellent chemical control of our synthetic technology versus the heterogeneous natural product adjuvants, as well as its streamlined, scalable nature and low-cost profile are unique attributes of our platform that will be valorised herein, making it a potentially superior alternative to existing vaccine models with less structural definition and costlier timelines. The main objectives are 1) demonstrate our synthetic technology platform for the gram-scale production and selection of a candidate adjuvant lead; and 2) implement valorisation opportunities and verify the potential of spin-off creation by establishing an optimal IPR and public/private funding roadmap plan.
Campo scientifico
Parole chiave
Programma(i)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Argomento(i)
Meccanismo di finanziamento
HORIZON-ERC-POC - HORIZON ERC Proof of Concept GrantsIstituzione ospitante
48160 DERIO VIZCAYA
Spagna